Article info

PDF

Original article
Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal

Authors

  • Naoki Ikenaga Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Zhen-Wei Peng Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA Department of Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China PubMed articlesGoogle scholar articles
  • Kahini A Vaid Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Susan B Liu Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Shuhei Yoshida Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Deanna Y Sverdlov Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Amanda Mikels-Vigdal Gilead Sciences, Foster City, California, USA PubMed articlesGoogle scholar articles
  • Victoria Smith Gilead Sciences, Foster City, California, USA PubMed articlesGoogle scholar articles
  • Detlef Schuppan Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA Institute of Translational Immunology and Research Center for Immune Therapy, University Medical Center, Mainz, Germany PubMed articlesGoogle scholar articles
  • Yury V Popov Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Yury V Popov, Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02115, USA; ypopov{at}bidmc.harvard.edu
View Full Text

Citation

Ikenaga N, Peng Z, Vaid KA, et al
Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal

Publication history

  • Received 21 June 2016
  • Revised 7 December 2016
  • Accepted 18 December 2016
  • Published in print 1 September 2017.
  • Published online 9 August 2017.
  • Published first 10 January 2017.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.